GlassScriptPhysician profile
Jeffrey S Crippin
NPI 1265458574
$119,913.91
in general payments reported to CMS, 2019-2025
9 companies · $4,921 in 2025
The $4,921 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2021: $1,410 · 2022: $7,903 · 2024: $40.51 · 2025: $4,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Travel and Lodging: $2,380 · Food and Beverage: $81.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $2,379.52 |
| Food and Beverage | $81.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $33,870.32 | 2019-2022 | |
| Abbvie INC. | $30,500.14 | 2019 | |
| Dova Pharmaceuticals | $21,426.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $20,439.62 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $10,960.56 | 2022-2025 | Liverty, Venovo |
| Alexion Pharmaceuticals, INC. | $2,550.00 | 2021-2022 | |
| Cook Medical LLC | $125.77 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.60 | 2024 | Voquezna |
| Novo Nordisk INC | $13.91 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Crippin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.